Natera announced a collaboration with the Federation Francophone de Cancerologie Digestive and CHU Dijon Bourgogne on the CIRCULATE-PRODIGE-70 study, a randomized, multicenter, prospective phase III clinical trial in France investigating molecular residual disease, or MRD-guided adjuvant treatment in stage II colorectal cancer patients. The study’s main objective is to determine the benefit of adjuvant chemotherapy in stage II CRC patients with detectable circulating tumor DNA post-surgery. Patients who are Signatera MRD-positive will be randomized to receive ACT or pursue observation. Patients who are Signatera MRD-negative will be treated according to the standard of care. Approximately 1,600 patients will be tested with Signatera, and a successful study result is expected to pave the way for the adoption and reimbursement of Signatera in France. The initial readout is expected in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NTRA:
- Updated KDIGO guidelines a catalyst for Natera, says Piper Sandler
- Natera price target raised to $110 from $70 at Piper Sandler
- New Share Price & Shareholder Rights Risk for Natera Inc. – What’s the Latest?
- CMS announcement positive for CareDx and Natera, says Craig-Hallum
- CMS says transplant patients can continue to access blood tests
